Randomized Phase II Trial of Adjuvant Combined Epigenetic Therapy With 5-azacitidine and Entinostat in Resected Stage I Non-small Cell Lung Cancer Versus Standard Care

Trial Profile

Randomized Phase II Trial of Adjuvant Combined Epigenetic Therapy With 5-azacitidine and Entinostat in Resected Stage I Non-small Cell Lung Cancer Versus Standard Care

Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Oct 2013

At a glance

  • Drugs Azacitidine (Primary) ; Entinostat (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 May 2013 New source identified and integrated (University of Southern California Norris Comprehensive Cancer Center; 2N11-3).
    • 01 May 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 13 Feb 2013 New source identified and integrated (Vanderbilt University Institutional Review Board; 120153).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top